Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 64 Published: June 27, 2022 Report Code: GDHC069CL

Focal segmental glomerulosclerosis market research report includes an assessment of the disease epidemiology, late- to mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Focal segmental glomerulosclerosis (FSGS). The report also analyzes the clinical and commercial landscapes of FSGS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, which is caused by diverse clinicopathological entities with different mechanisms of injury. The podocyte is the principal target of lesions, resulting in scar tissue formation on the glomeruli. They may be the target of injury through nonmechanical damages (immunologic, toxic, and viral), mechanical damages, and genetic disorders.

What are the key MoA in the focal segmental glomerulosclerosis market?

The key MoA in the focal segmental glomerulosclerosis market are Receptor Antagonist, Ion Channel Blcoker, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Inhibitor. Receptor Antagonist has the highest number of pipeline products.

Focal segmental glomerulosclerosis market, by MoA

Focal segmental glomerulosclerosis market, by MoA

For more MoA insights, download a free report sample

What are the key targets in the focal segmental glomerulosclerosis market?

The key targets in the focal segmental glomerulosclerosis market are Receptor, Ion Channel, Protein and Peptide, Biological, and Enzyme. Receptor has the highest number of pipeline products.

Focal segmental glomerulosclerosis market, by targets

Focal segmental glomerulosclerosis market, by targets

For more target insights, download a free report sample

What are the key RoA in the focal segmental glomerulosclerosis market?

The key RoA in the focal segmental glomerulosclerosis market are Oral, Injection, and Enteral. Oral has the highest number of pipeline products.

Focal segmental glomerulosclerosis market, by RoA

Focal segmental glomerulosclerosis market, by RoA

For more RoA insights, download a free report sample

What are the key molecule type in the focal segmental glomerulosclerosis market?

The key molecule type in the focal segmental glomerulosclerosis market are small molecule, biologic, oligonucleotide, and polymer. Small molecule has the highest number of pipeline products.

Focal segmental glomerulosclerosis market, by molecule type

Focal segmental glomerulosclerosis market, by molecule type

For more molecule type insights, download a free report sample

What are the key sponsors in the focal segmental glomerulosclerosis market?

Some of the key sponsors in the focal segmental glomerulosclerosis market are Goldfinch Bio, Mayo Clinic, Pfizer Inc, Dimerix Ltd, River 3 Renal Corp, Complexa Inc, and Travere Therapeutics. Goldfinch Bio and Travere Therapeutics have sponsored the largest number of clinical trials (three each) in FSGS over the past 10 years.

Focal segmental glomerulosclerosis market, by sponsors

Focal segmental glomerulosclerosis market, by sponsors

To know more about sponsors, download a free report sample

Market report overview

Key MoA Receptor Antagonist, Ion Channel Blcoker, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Inhibitor
Key targets Receptor, Ion Channel, Protein and Peptide, Biological, and Enzyme
Key RoA Oral, Injection, and Enteral
Key molecule type Small Molecule, Biologic, Oligonucleotide, and Polymer
Key sponsors Goldfinch Bio, Mayo Clinic, Pfizer Inc, Dimerix Ltd, River 3 Renal Corp, Complexa Inc, and Travere Therapeutics

Scope

GlobalData’s Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Overview by Molecule Type

4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Mechanism of Action

5.4 Overview by Route of Administration

5.5 Overview by Molecule Type

5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

Request a Free Sample
$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.